Upcoming Webinars
Friday, March 31, 2023
10:00AM EDT | 2:00PM UTC | 4:00PM CEST
Wednesday, April 19, 2023
12:00PM EDT | 4:00PM UTC | 6:00PM CEST
Wednesday, May 31, 2023
11:00AM EDT | 3:00PM UTC | 5:00PM CEST
Thursday, June 1, 2023
10:00AM EDT | 2:00PM UTC | 4:00PM CEST
Thursday, June 8, 2023
9:00PM EDT
Most Recent
Sponsored by ISPOR Patient-Centered Special Interest Group
Mar 2023
In this webinar series, we will hear from patient representatives and FDA staff to learn what is covered in this guidance series and what these new guidances mean for patient-focused drug development and the HEOR community.
Sponsored by Inovalon
Feb 2023
This webinar will focus on how integrating social determinants of health (SDOH) data with claims-based research can provide an opportunity to improve treatment access and outcomes for under-represented populations through targeted research and strategic efforts.
Sponsored by ISPOR Health Preference Research Special Interest Group
Feb 2023
The workshop will use real-time polling to understand the audience’s experiences with data collection fraud online and the methods used to prevent and identify data collection fraud. We will encourage audience members to share their own strategies, learnings, and challenges.
Sponsored by Parexel
Feb 2023
Focusing on clinical neurosciences (CNS), and using first-hand experience from a Parkinson’s study, experts from Parexel discuss how to integrate eCOA science and sensor technology into clinical trials.
Sponsored by ISPOR Patient-Centered Special Interest Group
Feb 2023
This is part one of a two-part webinar series. The FDA is developing Patient-Focused Drug Development (PFDD) guidance to inform the inclusion of patient experience when developing new medical therapies and products. This is a four-part guidance series, with two final guidances released, a third draft guidance released and a fourth guidance under development.
Sponsored by ISPOR Clinical Outcomes Assessment Special Interest Group
Jan 2023
An ageing population means an urgent need for better and effective treatment for age-related illnesses. Despite billion-dollar investments for drug development for these conditions, especially neurogenerative diseases, there is a low success rate and it is a slow process.
Clinical Outcomes
Sponsored by ISPOR Health Preference Research Special Interest Group
Feb 2023
The workshop will use real-time polling to understand the audience’s experiences with data collection fraud online and the methods used to prevent and identify data collection fraud. We will encourage audience members to share their own strategies, learnings, and challenges.
Sponsored by ISPOR Clinical Outcomes Assessment Special Interest Group
Jan 2023
An ageing population means an urgent need for better and effective treatment for age-related illnesses. Despite billion-dollar investments for drug development for these conditions, especially neurogenerative diseases, there is a low success rate and it is a slow process.
Sponsored by Evidera, a PPD Company
Oct 2022
One of the advantages of network meta-analyses (NMA) is the ability to use findings to draw conclusions regarding the best treatment for a given outcome. The Surface-Under-the-Cumulative-Ranking (SUCRA) is the most common method used to rank treatments in Bayesian NMAs, but it is often misinterpreted and misreported. This webinar will explore what the SUCRA is, demonstrate how it can be meaningfully impacted by network composition (even in simple networks), and suggest corrections to common errors in the reporting of SUCRAs.
Sep 2022
Asia Pacific regional markets, including but not limited to mainland China, Japan, South Korea and Taiwan, play increasingly important roles in global clinical development. Patient-centric endpoints via clinical outcome assessments (COAs) and electronic COAs (eCOAs), are getting more and more attention in clinical research design and execution.
Economic Evaluation
Oct 2022
Many health systems in Africa are generally characterized by high burden of out-of-pocket payment by patients at the point of care and increased exposure of clients to catastrophic health payments. However, there are recent moves by many African countries to improve their health financing systems and institute health insurance in a bid to ensure universal health coverage.
Sponsored by FIFARMA
Aug 2022
This is the Second webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams: (1) Funding: what is the relation between health & the economy and how to ensure the long term healthcare system sustainability, (2) Value: what are the value frameworks used by decision makers in LatAm and what is the impact on patient access, (3) Adoption: how to ensure access for the right patient, to the right treatment, at the right time.
Sponsored by FIFARMA
Jul 2022
This is the first webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams.
Jun 2022
This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).
Health Technology Assessment
Oct 2022
Many health systems in Africa are generally characterized by high burden of out-of-pocket payment by patients at the point of care and increased exposure of clients to catastrophic health payments. However, there are recent moves by many African countries to improve their health financing systems and institute health insurance in a bid to ensure universal health coverage.
Sponsored by Replica Analytics
Sep 2022
Sep 2022
Deliberative processes for health technology assessment (HTA) are intended to facilitate participatory decision making, using discussion and open dialogue between stakeholders. Increasing attention is being given to deliberative processes, but guidance is lacking for those who wish to design or use them. Health Technology Assessment International (HTAi) and ISPOR initiated a joint task force that developed comprehensive guidance to address this gap. This webinar will be of benefit to all those involved in establishing or improving deliberative processes for HTA in local contexts.
Sponsored by FIFARMA
Jul 2022
This is the first webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams.
Real-World Data & Information Systems
Sponsored by Inovalon
Feb 2023
This webinar will focus on how integrating social determinants of health (SDOH) data with claims-based research can provide an opportunity to improve treatment access and outcomes for under-represented populations through targeted research and strategic efforts.
Sponsored by Real-World Evidence- ISPOR Special Interest Group, and The International Society for Pharmacoepidemiology (ISPE)
Nov 2022
Real-World evidence (RWE) has recently received increased attention to provide supplementary evidence to support health technology assessment (HTA) submissions, especially as another source of insight into the real-world performance of novel therapeutic products, particularly when traditional randomized controlled trials (RCTs) are impractical or lack generalizability.
Sponsored by Replica Analytics
Sep 2022
Jul 2022
The key success factor for digital health implementation is the information sharing across multiple stakeholders engaged in the clinical decision making. The COVID pandemic revealed numerous differences in how individual data are used in the process of the adoption of various digital health solutions in the healthcare systems across the globe.
Patient-Centered Research
Sponsored by ISPOR Patient-Centered Special Interest Group
Mar 2023
In this webinar series, we will hear from patient representatives and FDA staff to learn what is covered in this guidance series and what these new guidances mean for patient-focused drug development and the HEOR community.
Sponsored by ISPOR Patient-Centered Special Interest Group
Feb 2023
This is part one of a two-part webinar series. The FDA is developing Patient-Focused Drug Development (PFDD) guidance to inform the inclusion of patient experience when developing new medical therapies and products. This is a four-part guidance series, with two final guidances released, a third draft guidance released and a fourth guidance under development.
Sponsored by GSK
Dec 2022
In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.
Sponsored by FIFARMA
Oct 2022
This webinar will focus on discussing how to ensure access for the right patient, to the right treatment, at the right time. We invited Max Newton, Engagement Manager at IQVIA as guest speaker. Max worked on the development of the FIFARMA "Patients Waiting to Access Innovative Therapies (WAIT) Indicator survey"; he also is leading a similar survey in Europe, the "EFPIA WAIT indicator".
Methodical & Statistical Research
Sponsored by FIFARMA
Oct 2022
This webinar will focus on discussing how to ensure access for the right patient, to the right treatment, at the right time. We invited Max Newton, Engagement Manager at IQVIA as guest speaker. Max worked on the development of the FIFARMA "Patients Waiting to Access Innovative Therapies (WAIT) Indicator survey"; he also is leading a similar survey in Europe, the "EFPIA WAIT indicator".
Sponsored by Evidera, a PPD Company
Oct 2022
One of the advantages of network meta-analyses (NMA) is the ability to use findings to draw conclusions regarding the best treatment for a given outcome. The Surface-Under-the-Cumulative-Ranking (SUCRA) is the most common method used to rank treatments in Bayesian NMAs, but it is often misinterpreted and misreported. This webinar will explore what the SUCRA is, demonstrate how it can be meaningfully impacted by network composition (even in simple networks), and suggest corrections to common errors in the reporting of SUCRAs.
Sponsored by Replica Analytics
Sep 2022
Sep 2022
The Statistical Methods in Health Economics and Outcome Research Special Interest Group is pleased to present two webinars on Network Meta-Analysis (NMA). The first one is an introduction to NMA by Emma Hawe. The second will cover special topics in NMA by Sofia Dias. Both webinars will be moderated by Gian Luca Di Tanna. The second webinar will feature more advanced content than the first webinar.
Health Policy & Regulatory
Sponsored by Charles River Associates
Oct 2022
Biosimilars offer great potential for the patients, payers and the whole society. However, there exist policy barriers which can hinder this potential. The debate will analyze the challenges and opportunities for biosimilars uptake in Europe, Middle East and Canada.
Oct 2022
Many health systems in Africa are generally characterized by high burden of out-of-pocket payment by patients at the point of care and increased exposure of clients to catastrophic health payments. However, there are recent moves by many African countries to improve their health financing systems and institute health insurance in a bid to ensure universal health coverage.
Sponsored by FIFARMA
Oct 2022
This webinar will focus on discussing how to ensure access for the right patient, to the right treatment, at the right time. We invited Max Newton, Engagement Manager at IQVIA as guest speaker. Max worked on the development of the FIFARMA "Patients Waiting to Access Innovative Therapies (WAIT) Indicator survey"; he also is leading a similar survey in Europe, the "EFPIA WAIT indicator".
Sponsored by Replica Analytics
Sep 2022
Study Approaches
Oct 2020
In this webinar, we will be discussing this issue in relation to cancer immunotherapy. An overview of the survival extrapolation methods which could be used for cancer immunotherapies will be presented along with an assessment of their strengths and limitations. Finally, the presenters will provide attendees with some pointers to help with the selection of appropriate survival extrapolation models for these agents.
Jun 2020
This webinar will explore why and how to use qualitative research methods in conjunction with discrete choice experiments in healthcare. Speakers will discuss formative qualitative research for the identification and generation of attributes and levels and qualitative research for testing survey comprehension and decision-making processes.
Apr 2020
This webinar will explore the value and challenges of linking administrative claims data to additional data sources in order to provide a more comprehensive look at the patient journey through a disease state. Data linkage types, techniques and best practices will be discussed.
Sponsored by FIFARMA
Oct 2022
This webinar will focus on discussing how to ensure access for the right patient, to the right treatment, at the right time. We invited Max Newton, Engagement Manager at IQVIA as guest speaker. Max worked on the development of the FIFARMA "Patients Waiting to Access Innovative Therapies (WAIT) Indicator survey"; he also is leading a similar survey in Europe, the "EFPIA WAIT indicator".
Sponsored by FIFARMA
Aug 2022
This is the Second webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams: (1) Funding: what is the relation between health & the economy and how to ensure the long term healthcare system sustainability, (2) Value: what are the value frameworks used by decision makers in LatAm and what is the impact on patient access, (3) Adoption: how to ensure access for the right patient, to the right treatment, at the right time.
Sponsored by FIFARMA
Jul 2022
This is the first webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams.
Sponsored by MDClone
May 2022
Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.
Sponsored by GSK
Dec 2022
In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.
Sep 2021
During this webinar, the speakers will present their respective studies on gene therapy in Duchenne muscular dystrophy, spinal muscular atrophy (SMA) and hemophilia. They will discuss the importance of the disease context, the qualitative research that influenced attribute selection, the selection of health preference method and design of the health preferences’ tasks, and how the study findings relate to the potential value of gene therapy.
Feb 2021
This webinar will present an insightful exchange on best practices, challenges and opportunities for market access of biosimilars in different regions worldwide.
Oct 2020
The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.
Sponsored by GSK
Dec 2022
In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.
Sponsored by Biogen
Feb 2021
This educational webinar will describe factors that affect the assessment of the clinical and economic value of medical innovations, highlight specific issues with relevance to the societal value of treatments for AD, and place these issues in the context of future health technology assessments for AD treatments.
Dec 2020
This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.
Nov 2020
This webinar will define how Alzheimer’s disease affects underserved communities; share opportunities to create more equitable, ethical, and inclusive value frameworks; and educate on the community’s role in solving this problem.
Need More Information or Have Questions?
Contact us for more information on ISPOR education and training.